Latest News

Syndesi swallowed by Abbvie

©Pixabay.com


by tg

AbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio.

Originally, Belgian Syndesi was created in 2017 through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors led by Novo Holdings to advance UCB’s SV2A modulator SDI-118. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission.

SDI-118 is currently evaluated in Phase Ib studies as a imodulator of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder.  

Under the terms of the agreement, AbbVie will pay Syndesi a $130m upfront and potential  milestone payments of up to $870m.

Noema Pharma AG closes Series B financing

CNS specialist Noema Pharma has cashed in €104m in an oversubscribed Series B fianancing co-led by Jeito Capital and Forbion. New investors such as...

Iktos SA raises €15.5m in Series A financing

aThe Series A financing of Iktos was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation...

Novartis in US$465m deal with 3B Pharmaceuticals GmbH

Under the agreement, which foresees US$425m in milestones plus royalities on future sales for 3B Pharmaceuticals GmbH (3BP), Basel-based pharma...

uniQure sells royalty interest in gene therapy for $400m

Phialogics AG bags pre-seed financing

Basel-based Phialogics AG, which was spun-off from Fraunhofer Institute for Immune Pathology and Immune Tolerance in 2021, has cashed in a pre-seed...

Genmab and argenx combine antibody know-how

Genmab A/S and argenx will start their collaboration jointly launching two antibody programmes in immunology and oncology with the...

Dualyx NV raises €40m in Series A financing

The Series A financing was co-led by Fountain Healthcare Partners, Forbion and Andera Partners and seed investors V-Bio Ventures, BGV, PMV, VIB,...